

## India Ratings : Info Center : Press Releases

## Ind-Ra Places Claris Lifesciences on RWP

Ind-Ra-Mumbai-2 April 2013: India Ratings & Research (Ind-Ra) has placed Claris Lifesciences Ltd's (Claris) Long-Term Issuer Rating of 'IND A-' on Rating Watch Positive (RWP). A list of additional rating actions is provided at the end of this commentary.

## **Key Rating Drivers**

The RWP reflects the likelihood of a significant improvement in Claris' credit profile post transfer of its infusions business in India and emerging markets, which accounted for more than half of its revenue, to a JV with Japan's Otsuka Pharmaceutical Factory and Mitsui & Co. The business is valued at INR13.13bn and Claris will receive a total cash consideration of INR10.50bn for the 80% stake sale. The deal is subject to regulatory approvals and other closing formalities and is likely to be completed by H1CY13.

Claris will use the cash proceeds from the JV transaction to prepay around INR3,000m of its outstanding debts, which will reduce its debt levels. The remaining proceeds will be used for growth capex and to reward the shareholders.

Claris' 2012 financial performance was in line with Ind-Ra's expectation. Revenue during 2012 grew 3.2% yoy to INR7.6bn, and EBITDA and EBITDA margins were higher at INR2.6bn and 34.7% versus INR2.5bn and 33.5% in 2011. Credit metrics were comfortable with financial leverage (adjusted debt net of cash) of 1.72x in 2012, up from 1.25x in 2011 due to a 32% yoy increase in debt from higher capex spends.

Post the sale of the infusion business, Claris will expand its specialty generic injectables business in all international markets, especially the regulated markets of the USA and EU via new product launches. With the reinstatement of the US Food and Drug Administration (USFDA) approval certification in August 2012, Claris will resume sales to the US market. However, contrary to the past, it seeks to directly penetrate the market versus through a partnership. Also, the company is looking at bringing more high-value products in the injectables segment and invest into new products for regulated markets. The company will also work on fast track growth opportunities via organic and inorganic routes.

## **Rating Sensitivities**

Ind-Ra expects to resolve the RWP after the completion of the business transaction. The RWP indicates that the ratings may be upgraded or affirmed upon resolution.

Rating actions on Claris' bank loan ratings are as follows:

- INR2.2bn term loans: Long-Term 'IND A-' placed on RWP
- INR1.8bn fund-based cash credit limits: Long-Term 'IND A-' placed on RWP
- INR175m fund-based limits: affirmed at Short-Term 'IND A1'
- INR705m non-fund-based limits: affirmed at Short-Term 'IND A1'

Contacts: Primary Analyst Ashwini Picardo Associate Director +91 22 4000 1787 India Ratings and Research Pvt Ltd Wockhardt Tower, Level 4, West Wing Bandra Kurla Complex, Bandra (East) Mumbai 400 051

Secondary Analyst Carrol D'silva Analyst +91 22 4000 1731

Committee Chairperson Sreenivasa Prasanna Senior Director +91 44 4340 1711

Media Relations: Saraanya Shetty, Mumbai, Tel: + 91 22 4000 1729, Email: saraanya.shetty@indiaratings.co.in.

Additional information is available at <u>www.indiaratings.co.in</u>. The ratings above were solicited by, or on behalf of, the issuer, and therefore, India Ratings has been compensated for the provision of the ratings.

Ratings are not a recommendation or suggestion, directly or indirectly, to you or any other person, to buy, sell, make or hold any investment, loan or security or to undertake any investment strategy with respect to any investment, loan or security or any issuer.

Applicable criteria, 'Corporate Rating Methodology', dated 12 September 2012, are available at <u>www.indiaratings.co.in</u>.

ALL CREDIT RATINGS ASSIGNED BY INDIA RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS. PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK: <u>HTTP://INDIARATINGS.CO.IN/UNDERSTANDINGCREDITRATINGS.JSP</u>. IN ADDITION, RATING DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S PUBLIC WEBSITE '<u>WWW.INDIARATINGS.CO.IN'</u>. PUBLISHED RATINGS, CRITERIA, AND METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. INDIA RATINGS CODE OF CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE, AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE CODE OF CONDUCT SECTION OF THIS SITE

India Ratings & Research (India Ratings) has six rating offices located at Mumbai, Delhi, Chennai, Kolkata, Bangalore and Hyderabad. India Ratings is recognised by Reserve Bank of India, Securities Exchange Board of India (SEBI) and National Housing Bank.

\*\*\*

\*\*\*